Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ANG Lifesciences India Ltd has submitted copies of newspaper advertisements of its audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026, as required under SEBI listing rules. The ads were published in Business Standard (English) and Aj Di Awaaz (Punjabi) on June 1, 2026. Key highlights from the results: full-year FY26 standalone revenue was nearly flat at around Rs. 92.33 crore vs Rs. 92.35 crore in FY25, but the net loss narrowed sharply to about Rs. 4.73 crore from Rs. 10.34 crore a year ago. In Q4 FY26, the company swung to a standalone profit of about Rs. 1.10 crore versus a loss of Rs. 1.94 crore in Q4 FY25. On a consolidated basis, the full-year loss also improved to about Rs. 11.08 crore from Rs. 12.41 crore in FY25. The results were approved by the board on May 30, 2026.
This is a routine regulatory disclosure republishing already-approved results, so no fresh news shock for shareholders. The narrower losses and return to quarterly profitability are mildly positive, but the company remains loss-making for the full year, so the underlying picture has not turned around.